News Related to Urothelial Carcinoma

Related coverage linked through entity extraction aliases.

Enfortumab Vedotin Plus Pembrolizumab Improves Survival in Muscle-Invasive Bladder Cancer

Mar 05, 2026

Phase III KEYNOTE-B15 trial demonstrates enfortumab vedotin plus pembrolizumab significantly improves event-free survival and pathologic complete response rates compared with cisplatin-based chemotherapy in muscle-invasive bladder cancer.

FDA Approves KEYTRUDA for Platinum-Resistant Ovarian Cancer

Feb 15, 2026

The FDA approved KEYTRUDA and its subcutaneous QLEX formulation for platinum-resistant ovarian cancer, marking the first PD-1 inhibitor cleared for this patient population based on Phase 3 results.